SS18 and neoplasm: The chromosomal translocation in synovial sarcoma results in a SS18-SSX fusion protein [111] and it has been demonstrated that circulating CD8+ T cells of HLA-A24+ synovial sarcoma patients can recognise the SS18-SSX peptides and mediate tumour-specific immune responses [112,113].